Evidence map›Paper›PMID 24752651›Full record

ArticleInternational journal of cancer2014

ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models.

Aijaz Parray, Hifzur R Siddique, Jacquelyn K Kuriger, Shrawan K Mishra, Johng S Rhim, Heather H Nelson, Hiroyuki Aburatani, Badrinath R Konety, Shahriar Koochekpour, Mohammad Saleem

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Race and prostate cancer: genomic landscape.Nature reviews. Urology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. HighJournal of Cancer · 2021
    Article
  14. Article
  15. Identifying and treating ROBO1The Prostate · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Aijaz ParraySection of Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, MN.
Hifzur R Siddique
Jacquelyn K Kuriger
Shrawan K Mishra
Johng S Rhim
Heather H Nelson
Hiroyuki Aburatani
Badrinath R Konety
Shahriar Koochekpour
Mohammad Saleem
University of Minnesota · USHormel (United States) · USRoswell Park Comprehensive Cancer Center · USThe University of Tokyo · JPUniformed Services University of the Health Sciences · USUniversity of Minnesota Medical Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Prognostic value of AR mutation in primary African American prostate cancerR21CA143589 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KOOCHEKPOUR, SHAHRIAR · 2010 to 2011
$353k
NCI NIH HHS P30 CA016056NCI NIH HHS P30CA016056NCI NIH HHS R21 CA143589NCI NIH HHS R21CA143589
6 · The paper itself

Abstract

High-risk populations exhibit early transformation of localized prostate cancer (CaP) disease to metastasis which results in the mortality of such patients. The paucity of knowledge about the molecular mechanism involved in acquiring of metastatic behavior by primary tumor cells and non-availability of reliable phenotype-discriminating biomarkers are stumbling blocks in the management of CaP disease. Here, we determine the role and translational relevance of ROBO1 (an organogenesis-associated gene) in human CaP. Employing CaP-progression models and prostatic tissues of Caucasian and African-American patients, we show that ROBO1 expression is localized to cell-membrane and significantly lost in primary and metastatic tumors. While Caucasians exhibited similar ROBO1 levels in primary and metastatic phenotype, a significant difference was observed between tumor phenotypes in African-Americans. Epigenetic assays identified promoter methylation of ROBO1 specific to African-American metastatic CaP cells. Using African-American CaP models for further studies, we show that ROBO1 negatively regulates motility and invasiveness of primary CaP cells, and its loss causes these cells to acquire invasive trait. To understand the underlying mechanism, we employed ROBO1-expressing/ROBO1-C2C3-mutant constructs, immunoprecipitation, confocal-microscopy and luciferase-reporter techniques. We show that ROBO1 through its interaction with DOCK1 (at SH3-SH2-domain) controls the Rac-activation. However, loss of ROBO1 results in Rac1-activation which in turn causes E-Cadherin/β-catenin cytoskeleton destabilization and induction of cell migration. We suggest that ROBO1 is a predictive biomarker that has potential to discriminate among CaP types, and could be exploited as a molecular target to inhibit the progression of disease as well as treat metastasis in high-risk populations such as African-Americans.

Indexed as

Genes, Tumor Suppressorbeta CateninBlack or African AmericanBlotting, WesternCadherinsCell MovementCell ProliferationCohort StudiesDisease ProgressionFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunoenzyme TechniquesMaleNeoplasm MetastasisNeoplasm Stagingbeta CateninCadherinsDOCK1 protein, humanNerve Tissue Proteinsrac1 GTP-Binding ProteinRAC1 protein, humanrac GTP-Binding ProteinsReceptors, ImmunologicRNA, MessengerRNA, Small InterferingRoundabout ProteinsAfrican-Americanindolentmetastaticprostate cancerROBO1

Identifiers

PMID24752651
PMCPMC4610361
OpenAlexW1940832933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.